What Did This CEO Just Do with Personal Shares of Ligand Pharma (NASDAQ: LGND)?

By Carrie Williams

Today, the CEO of Ligand Pharma (NASDAQ: LGND), John L. Higgins, sold shares of LGND for $903.9K.

Following John L. Higgins’ last LGND Sell transaction on November 20, 2017, the stock climbed by 127.1%. In addition to John L. Higgins, 4 other LGND executives reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Ligand Pharma’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $90.04 million and quarterly net profit of $73.16 million. In comparison, last year the company earned revenue of $28 million and had a net profit of $6.06 million. LGND’s market cap is $5.43B and the company has a P/E ratio of 53.16. Currently, Ligand Pharma has an average volume of 123.5K.

Based on 6 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $255.17, reflecting a -0.7% downside.

The insider sentiment on Ligand Pharma has been negative according to 62 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.